ISB 2301
Alternative Names: ISB-2301Latest Information Update: 28 Aug 2023
At a glance
- Originator Ichnos Sciences
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 23 Jun 2023 ISB 2301 is available for licensing as of 23 Jun 2023. https://ichnossciences.com/partnership/ (Ichnos Sciences website, June 2023)
- 23 Jun 2023 Early research in Solid tumours in USA (Parenteral) (Ichnos Sciences pipeline, June 2023)